Eph receptors comprise the largest family of receptor tyrosine kinases (RTKs), with fourteen receptors divided into two subfamilies -EphAs and EphBs. Yet, despite their multitude of functions in almost all tissues of the body, these receptors represent one of the most underappreciated RTK families. What makes Eph receptors unique is that their cognate ligands, the ephrins, are tethered to the cell surface, in contrast to other RTKs whose ligands are generally soluble. This phenomenon means that signalling through Eph receptors is largely dependent on cell-cell contact. In this way, Eph receptors allow cells to sense their immediate surrounding cellular microenvironment and make appropriate behavioural decisions. For example, Eph receptors control whether two contacting cells are repelled by, or attracted to, each other. As such, they play an important role in normal physiological processes, including embryonic tissue boundary formation and directional guidance of developing axons, while in adult tissues they aid in wound healing and the maintenance of intestinal cell populations in particular compartments. Aberrant expression of these receptors, however, has been implicated in many pathologies, including cancer and neurodegenerative diseases. In this Primer we will discuss some of the key aspects of signalling by Ephs and ephrins that make them pivotal players in health and disease.
Eph and ephrin structure Eph receptors were fi rst identifi ed in 1987, during a screen for new oncogenic tyrosine kinases. The term Eph receptor comes from 'erythropoietin-producing hepatocellular carcinoma cell line', the cell line from which their cDNA was originally isolated. Since then a whole family of receptors and ligands have been identifi ed and further categorised based on their sequence homology.
Primer
Eph receptors are divided into two subfamilies, the type A Eph receptors (EphA1-EphA8 and EphA10), which bind to and activate type A ephrins (ephrin-A1-ephrin-A5), and the type B Eph receptors (EphB1-EphB4 and EphB6), which bind to and activate the type B ephrins (ephrin-B1-ephrin-B3). There is a degree of promiscuity between categories; for example, EphB2 can bind ephrin-A5, and EphA4 is able to bind ephrin-B ligands. There is also promiscuity of binding within categories, for example EphB2 is able to bind to ephrin-B1, -B2 and -B3. This 'redundancy' can make knockout studies diffi cult to interpret.
EphA and EphB receptors have a similar structure; extracellularly they have a ligand-binding domain and a cysteine-rich region (Cys domain) followed by two fi bronectin type III repeat domains. A single transmembrane region is then followed by an intracellular juxtamembrane domain, which is important for receptor activation, a kinase domain, a sterile alpha motif (SAM), which is required for receptor oligomerisation, and a PDZ domain binding site.
In contrast, the structures of the ligand classes, ephrin-As and -Bs, are very different from each other. Ephrin-B ligands contain an extracellular receptor-binding domain, a short transmembrane domain and a short cytoplasmic tail, which has conserved tyrosine residues, and a PDZ-domain-binding site. Ephrin-As are smaller with only a receptor-binding domain tethered to the membrane via a glycosylphosphatidylinositol (GPI) anchor.
Ephrin-Eph signalling
Because their ephrin ligands are membrane tethered, Eph receptors are activated by cell-cell contact; the ligand-binding domain of the Eph receptor interacts with the extracellular domain of the ephrin ligand expressed on a neighbouring cell. A novel aspect of the ephrin-Eph interaction is that the resultant signalling can occur in a bidirectional manner. Signalling through the Eph receptor has been termed forward signalling, while signalling through the ephrin ligand has been termed reverse signalling (Figure 1 ).
Forward signalling
Signalling through activation of Eph receptors by ephrins expressed on another cell is considered to be the canonical signalling pathway. It can take the form of receptor autophosphorylation, or phosphorylation of associated effector proteins. A recently resolved X-ray crystal structure of EphB2 has revealed that the phosphorylation of conserved tyrosine residues in the Eph juxtamembrane region causes the receptor to adopt an open conformation, allowing further tyrosine phosphorylation of the active site of the kinase domain. Adaptor molecules containing Src homology 2 (SH2), SAM or PDZ domains can then bind and activate further downstream signalling events. As a rule, and contrary to the function of many other RTKs, Eph receptors do not directly regulate cell growth through the Ras-MAPK pathway.
Reverse signalling
Although less is known about reverse signalling, it is clear that ephrins possess a degree of signalling function. Ephrin-Bs contain fi ve conserved intracellular tyrosine residues, which are phosphorylated by Src family kinases upon EphB receptor engagement. The intracellular tail of ephrin-Bs also contains a PDZ-binding domain, just like the Eph receptors, allowing PDZ-domaincontaining proteins to bind. It has been shown that the protein tyrosine phosphatase PTP-BL is recruited to ephrin-B upon stimulation and acts to inhibit ephrin-B phosphorylation, thereby inducing a switch from phosphorylation-dependent to PDZ-dependent signalling. Ephrin-A reverse signalling is less well characterised. How a signal is transmitted from the extracellular ephrin, through a GPI anchor, to within the cell remains to be fully elucidated. What is clear, however, is that ephrin-A reverse signalling is dependent upon other proteins, such as the Src family kinase Fyn, being recruited to ephrin complexes. To add further complexity, Eph receptors can also interact in cis with ephrins co-expressed on the same cell membrane. This interaction has been found to inhibit forward signalling through the Eph receptor. Equally, because a cell will express varying levels of different Eph receptor and ephrin subtypes on its surface, the behaviour of the cell upon interaction with another cell will be a function of the relative ratios of these receptor and ligand subtypes. For example, for prostate cancer cells, whether the cancer cell is attracted to or repelled by neighbouring stromal cells is dictated by the combination of Eph receptors that are expressed and thereby activated by cell-cell contact.
Signalling complexity
Once activated, Eph receptors may also affect other signalling pathways; for example, there is increasing evidence that Ephs and ephrins can also interact with other RTKs. ErbB2 (HER-2) can associate with EphA2, resulting in EphA2 phosphorylation, followed by increased activation of Rho GTPases and Ras/ERK signalling, and subsequently pro-oncogenic effects, such as increased cancer cell motility and proliferation ( Figure 1 ).
Perhaps because of the complexities of Eph signalling, the intracellular signalling pathways downstream of specifi c Ephs have yet to be fully elucidated. Much of the original work in this area utilised artifi cial soluble ephrin ligands, an approach which has certainly provided many useful insights; however, recent advances have come from more physiologically relevant experiments using quantitative proteomic analysis. This approach involves co-culturing two labelled cell populations and using cell-surface-bound ephrins on one cell type to activate the Eph receptors on the other cell type. The tyrosine-phosphorylated peptides from each cell type can then be identifi ed and quantifi ed using mass spectrometry. When EphB2-and ephrin-B1-expressing cells were co-cultured, it became apparent that the bidirectional signalling was asymmetrical between the two cell types, and that the two cell populations were transmitting the signals induced by cell-cell contact using very different tyrosine kinases and downstream target proteins (Figure 1 ).
Eph signalling idiosyncrasies
Interestingly, Eph receptors can also signal in a ligand-independent manner, particularly in situations where they are overexpressed, such as in cancer cells. For example, EphA2 is able to function in both an inhibitory and an oncogenic fashion, depending on the presence or absence of its ligand ephrin-A1. Ligand-independent signalling, triggered for example by growth factors in serum, has been shown to involve activated Akt, which phosphorylates EphA2 at S897 leading to increased cell polarity, lamellipodial protrusion, and subsequently increased cell migration and invasion (Figure 1) . Conversely, in the presence of ephrin-A1, EphA2 is phosphorylated at the juxtamembrane tyrosine residues and dephosphorylated at S897. This ligand-activated EphA2 then deactivates Akt, leading to the disappearance of phosphorylated Akt from the leading edge of the cell. Stimulation by ephrin-A1 results in retraction of lamellipodia and a reduction in chemotactic cell migration and invasion. S897 is only conserved between EphA2 and EphA1, suggesting that ligandindependent activation via Akt is restricted to these two receptors.
A recent exciting fi nding is that cells can deploy Eph receptors, specifi cally EphB2, on extracellular vesicles called exosomes. These vesicles offer a form of communication between cells that can occur at a distance yet can In the absence of its ligand, EphA2 can signal via a ligand-independent pathway. The stimulus for this could, for example, be activation of growth factor receptors, which leads to phosphorylation of Akt at T308 and S473. Akt in its activated form can then phosphorylate EphA2 at S897, resulting in increased cell polarity, lamellipodial protrusion and subsequently increased cell migration and invasion.
R92 Current Biology 27, R83-R102, February 6, 2017 mimic cell-cell contact (Figure 1) . Importantly, the EphB2 on neuronal exosomes has been shown to be functional, triggering ephrin-B reverse signalling and growth cone collapse in target cells. Current Biology 27, R83-R102, February 6, 2017 R93 route to ensure they do not stray off course. Eph-ephrin interactions play an essential part in this process. For example, ephrin-expressing stromal cells can repel a neuronal growth cone expressing the corresponding Eph receptor from entering their territory. In contrast, a different Eph receptor expression profi le on the growth cone can result in it being attracted to an ephrin-expressing area ( Figure 2B ). Ephrin-Eph signalling also restricts cell intermingling at key tissue boundaries (Figure 2A ). In the brain, Ephs and ephrins are expressed in complementary patterns, with signalling leading to cell repulsion and, as a result, prevents cell intermingling. Correct expression of Ephs and ephrins is critical in brain development; indeed, loss of EphB2 or EphB3 causes aberrant formation of the cerebral hemispheres.
Functions of ephrin-Eph signalling

Tissue maintenance
Eph receptors not only have a vital role in many developing tissues, they are also essential in maintaining the appropriate structure of tissues in adult organisms. A good example of this is in the epithelial crypts of the small intestine ( Figure 2D The effect of ephrin-Eph signalling on cell-cell junctions is also evident in wound repair. Upon wounding, EphBs and ephrin-Bs are upregulated in epidermal cells located back from the wound edge. Signalling between the receptor and ligand leads to a loosening of adherens junctions between cells and the dissolution of stress fi bres. This results in tension release within the epidermal monolayer, aiding collective cell migration and allowing the wound to close ( Figure 2C ).
Adhesion, attraction, repulsion and the infl uences on cell migration
The complete functions of Ephs and ephrins in cell-matrix adhesion are still being pieced together. Forward signalling through EphA2 downregulates integrin function, thus reducing cell migration and integrinmediated adhesion. In contrast, coupling of EphB1 and ephrin-B1 in vitro leads to increased cell adhesion via 15 integrin activation, an effect that is dependent on the surface density of ephrin-B1 expression. It seems likely that cellular adhesion is dictated by the balance of the expression of Eph receptors and ephrins on neighbouring cells.
As Ephs and ephrins are activated by cell-cell contact, they are perfectly placed to control whether a cell is attracted to, or will avoid, an adjacent cell. A common consequence of Eph signalling, therefore, is alteration in the actin cytoskeleton to regulate cell movement, and this is most often accomplished by modulation of Rho family GTPases. This family of molecular switches modulates cell movement by promoting the formation of different actin structures required for cellular migration. The three key players in this family are RhoA, Rac1 and Cdc42, and ephrin-Eph signalling can both promote and inhibit the activation of all of these GTPases. For example, in neurones, stimulation of cells with ephrin-A5 leads to growth cone collapse via activation of Rho, which causes cell contraction, and inhibition of Rac, which prevents lamellipodia formation.
Eph receptors and ephrins effect activation changes in these small GTPases via GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). A nice example of this is demonstrated in mice with a homozygous mutation in the gene encoding the RacGAP -chimerin. Mice with this mutation (termed miffy) have a distinctive 'rabbit-hopping' gait, identical to that resulting from loss of EphA4 and ephrin-B3. The origin of this abnormal gait was found following examination of the mouse corticospinal tract (CST), the neuronal pathway that controls voluntary limb movement. In wild-type mice, the CST originates in the cerebral hemisphere before crossing over the midline to the contralateral spinal cord. Re-crossing is then prevented through the expression of ephrin-B3 at the midline, which activates EphA4 on the axonal growth cone, inactivating Rac via -chimerin and resulting in repulsion. In miffy, -Chn
-/-or ephrin-B3 -/-mice, however, this repulsion does not take place and the CST recrosses to the ipsilateral spinal cord, resulting in the unusual hopping gait.
Cancer
Changes in Eph receptor expression levels occur in nearly all types of cancer, with altered expression being linked to disease stage and prognosis. EphA2 is upregulated in many different cancers, including breast, melanoma, prostate, ovarian and glioblastoma, with overexpression commonly being associated with a more advanced stage of disease and a poor prognosis. The mechanisms by which Ephs and ephrins contribute to tumour progression are complex and not fully understood, but they have been implicated in cancer cell proliferation, adhesion, migration, tumour angiogenesis and invasion. Eph receptor signalling in cancer remains bidirectional; however, studies have shown that both forward or reverse signalling can result in either oncogenic or tumour suppressor effects. For example, in many cancers EphA2 appears to have a tumour suppressor function when stimulated by its ephrin ligand. However, when overexpressed, EphA2 is activated in a ligand-independent manner and under these circumstances becomes R94 Current Biology 27, R83-R102, February 6, 2017 oncogenic. In breast cancer, EphA2 and EphB4 receptors are upregulated and associated with a poor prognosis; however, expression of their partner ligands, ephrin-B2 and ephrin-A1, is low, as is the tyrosine phosphorylation level of the Eph receptors themselves. We now know that under these circumstances EphA2 and EphB4 signal in an ephrin-independent manner and can induce pro-oncogenic effects through crosstalk with other signalling pathways, such as those downstream of the EGF receptor and ErbB2.
Another complexity of the ephrinEph system in cancer is that a particular Eph receptor can inhibit tumour progression in one cancer type but act in a tumour-promoting manner in a different cancer type. For example, in colon cancer low levels of EphB2 are associated with a poorer prognosis. In normal circumstances EphB2 expression is regulated by Wnt signalling in the colon and acts as a tumour suppressor. During the early stages of colorectal cancer, Wnt signalling becomes hyperactivated, leading to increased expression of EphB2. As a distortion of the normal physiology mentioned earlier in this article, high ephrin-B expression in epithelial cells at the top of intestinal crypts interacts with the EphB2 on the cancer cells, repelling them and preventing their migration out of the crypt. After the initial tumour proliferation phase, however, expression of EphB2 on the cancer cells is downregulated, allowing these cells to migrate unimpeded to other areas of the colon. In contrast, in breast cancer and ovarian cancer, high levels of EphB2 expression are associated with a worse prognosis.
Memory and neurodegenerative disease
In recent years Ephs and ephrins have been found to play a key role in the formation of memory and in pathologies of memory formation, such as Alzheimer's disease. Our long-and short-term memories are formed through alterations in synaptic neurotransmission. Eph receptors and ephrins are expressed both pre-and post-synaptically and are perfectly placed to effect such changes. In addition, both Ephs and ephrins are found in areas of the brain that are involved in memory formation, such as the hippocampus, amygdala and cortex. Alteration of synaptic transmission can be implemented in various ways, including changes in peri-synaptic neuronal morphology, changes in pre-synaptic transmitter release, or changes in the post-synaptic response to these transmitters. Eph receptors and ephrins have been shown to play a role in all of these processes via regulation of dendritic spine morphogenesis, pre-synaptic transmitter release, post-synaptic glutamate receptor traffi cking, and glutamate reuptake.
In the context of Alzheimer's disease, Eph receptors potentially represent an exciting new therapeutic opportunity. Post-mortem studies in humans show a reduction in EphA4 and EphB2 expression in the hippocampal tissue of patients with incipient Alzheimer's disease. Similar reductions in hippocampal EphA4 and EphB2 levels are seen in the Alzheimer's disease mouse model, prior to the development of overt cognitive impairment. -amyloid plaques are pathognomonic of Alzheimer's disease and -amyloid oligomers have been shown to reduce Eph receptor levels by triggering Eph receptor degradation by the proteasome. If Eph receptor function is artifi cially restored, this can reduce -amyloid-induced neuronal toxicity. One potential mechanism for this effect is the crosstalk between Eph receptors and the NMDA glutamate receptor. EphB has been shown to interact with NMDA at synapses, with stimulation by ephrin-B leading to NMDA clustering and calcium fl ux. This interaction may have important consequences in Alzheimer's disease since -amyloid plaques inhibit NMDA function, leading to impaired memory function. Expressing EphB2 in a mouse model of Alzheimer's disease rescues NMDA function and restores memory (Figure 3 ).
Future perspectives
The list of functions attributed to ephrin-Eph signalling is growing year on year. In addition to cancer, we are now starting to better understand how dysfunction of Eph receptors contributes to pathologies such as Alzheimer's disease and abnormal wound repair. Numerous therapeutic agents that target Eph receptors are currently being investigated, including 
